Publicacions en què col·labora amb Sandra Rayego Mateos (8)

2023

  1. BET Protein Inhibitor JQ1 Modulates Mitochondrial Dysfunction and Oxidative Stress Induced by Chronic Kidney Disease

    Antioxidants, Vol. 12, Núm. 5

  2. Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

2022

  1. Ccn2 increases tgf‐β receptor type ii expression in vascular smooth muscle cells: Essential role of ccn2 in the tgf‐β pathway regulation

    International Journal of Molecular Sciences, Vol. 23, Núm. 1

  2. Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis

    Pharmaceuticals, Vol. 15, Núm. 2

2019

  1. Bromodomain and extraterminal proteins as novel epigenetic targets for renal diseases

    Frontiers in Pharmacology, Vol. 10

2018

  1. Epigenetic modification mechanisms involved in inflammation and fibrosis in renal pathology

    Mediators of Inflammation, Vol. 2018

2017

  1. Inhibition of bromodomain and extraterminal domain family proteins ameliorates experimental renal damage

    Journal of the American Society of Nephrology, Vol. 28, Núm. 2, pp. 504-519

2013

  1. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response

    Laboratory Investigation, Vol. 93, Núm. 7, pp. 812-824